{"data":{"id":"us-sc/s.c.-code-ann.-44-53-1830","jurisdiction":"us-sc","citation":"S.C. Code Ann. § 44-53-1830","heading":"Cannabidiol for use in clinical trials.","body":"(A) Expanded access clinical trials conducted pursuant to a statewide investigational new drug application established pursuant to this chapter only shall utilize cannabidiol which is:\n(1) from an approved source; and\n(2) approved by the United States Food and Drug Administration to be used for treatment of a condition specified in an investigational new drug application.\n(B) The principal investigator and any subinvestigator may receive cannabidiol directly from an approved source or authorized distributor for an approved source for use in the expanded access clinical trials.","path":["Title 44 - HEALTH","CHAPTER 53 Poisons, Drugs, and Other Controlled Substances","ARTICLE 18 Julian's Law, Cannabidiol in Clinical Trials to Treat Patients with Epilepsy"],"source_url":"https://www.scstatehouse.gov/code/t44c053.php","current_through":"2025 Session of the General Assembly","vintage":"","retrieved_at":"2026-09-02T07:33:34Z","sha256":"0ac0befbdd501c53c083ec376bf2b535de3dca729cdc13b95f363eb55633e87e","source_id":"us-sc","stale":false,"prev":"us-sc/s.c.-code-ann.-44-53-1820","next":"us-sc/s.c.-code-ann.-44-53-1840"},"notice":"GroundRules: Original legal text. Not legal advice."}